about
Use of Bakri balloon tamponade in the treatment of postpartum hemorrhage: a series of 50 cases from a tertiary teaching hospitalFour year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trialChapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries.The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials.Treatment for cervical intraepithelial neoplasia and subsequent IVF deliveries.A discrepancy of Chlamydia trachomatis incidence and prevalence trends in Finland 1983-2003.Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trialImpact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot studyRisk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.Two intrauterine rescue transfusions in treatment of severe fetomaternal hemorrhage in the early third trimester.Once-daily valacyclovir to reduce the risk of transmission of genital herpes.Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up.Interruption of CXCL13-CXCR5 axis increases upper genital tract pathology and activation of NKT cells following chlamydial genital infection.Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial.Maternal deaths in Finland: focus on placental abruption.The accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic review.Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex tCost-effectiveness of hysterectomy for benign gynecological conditions: a systematic review.Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study.Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.Placenta previa percreta left in situ - management by delayed hysterectomy: a case report.Periodontal disease and bacterial vaginosis increase the risk for adverse pregnancy outcomeChlamydia trachomatis infection and risk of cervical intraepithelial neoplasiaManagement of Foley catheter induction among nulliparous women: a retrospective study.Transient urinary retention and chronic neuropathic pain associated with genital herpes simplex virus infection.Levonorgestrel-releasing intrauterine system in the treatment of heavy menstrual bleeding.Randomised trial on treatment of vaginal intraepithelial neoplasia-Imiquimod, laser vaporisation and expectant management.Sound efficacy of prophylactic HPV vaccination: Basics and implications.Human papillomavirus infection and the development of cervical cancer and related genital neoplasias.Introducing human papillomavirus vaccines - questions remain.Strengthening prevention programs to eliminate cervical cancer in the Nordic countries.Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observationAge for HPV vaccination.Surgical treatment of vulvar vestibulitis: a review.Chlamydia trachomatis infections of the female genital tract: state of the art.Population-Based Study of Prediagnostic Antibodies to Chlamydia trachomatis in Relation to Adverse Pregnancy Outcome.Changes over time in the Chlamydia trachomatis serotype distribution in Finnish women.Order of HPV/Chlamydia infections and cervical high-grade precancer risk: a case-cohort study.
P50
Q28273460-AB121689-BB89-4247-B28E-A5380A36AA37Q28750269-39454E97-04D7-4E89-BE31-71BFA2DD439FQ30230410-4E4A5712-63A7-4606-8013-96589E0CB452Q30450948-349C5FA6-DE14-4FD4-8D59-DBC93EEF0A0DQ33352626-69C683C0-8FDA-4DA7-A366-A108D0BD7019Q33394372-065943FF-E86A-42AA-9312-1C102E88A93FQ33626255-96802E57-3594-4260-A7EC-623C097EA560Q33929216-BCDDCB9A-4915-4A0D-9FC0-7CD358E4C7EAQ33953881-A9C408AF-A85B-4B74-A693-A6BE9AF19FBAQ34210255-71B2EF77-D2E5-4AE7-AB58-0A3675EF8ECFQ34286953-5821E049-62A2-458E-862E-E9F503929B1FQ34287411-18B5BC16-C347-4AD5-BA49-C57CE1230FADQ34308164-0AAEDF89-33FB-4067-AA75-8BE60D9DB9FCQ34493665-622091D8-2822-4D35-9C39-F88478EB37A0Q34580726-7AFC103A-EDEB-46C4-93F6-1725F8AB6E68Q34610151-052A9130-034E-4A6C-B5EC-EB577A7CC0E5Q34611218-944F6EF7-B3A5-434E-AB74-3B249CEC420DQ35017187-BD83298D-57F7-402B-B1BD-6E8A98586932Q35021139-A5A4086F-5920-4873-80D8-D020E2686752Q35030338-80016F47-33D9-4A94-B557-4D252E81D253Q35048280-7DD96526-352E-4546-8B05-F878E4666165Q35221177-C5792D4B-30E4-4417-B3C6-AE508289F128Q35226045-994037AB-4E26-4B68-ACA0-EE9899AB8816Q35614496-62A3DDAD-9949-43CD-AFD3-018B89061495Q35656638-C5D99907-7A21-4348-AD2F-C6EF6EEFED5BQ35823818-8D3564EE-F5A4-4637-8CB2-14BBB9557D25Q35904033-0C96F662-63DB-414F-AB9C-F1A3ECE5E368Q35943861-F677BDAD-1232-458B-BC7B-BCEA66CAE55DQ36080208-5D57DCE6-A93A-4517-A172-DBA0E0E6680AQ36373404-21B0CCF7-FE4D-4D7E-8CBF-C29FA32996A4Q37046156-9D695117-BC8F-4BC4-A348-FE3FD77138D7Q37126067-C17EE0EC-7140-4C40-9412-753B3D29228EQ37150889-AFE02077-63CD-400B-9391-3B67D2D45019Q37213042-B84DF2DD-3211-4190-89EA-A43E18FBA39CQ37222480-CF42A390-84B5-4B65-A852-2FDB2566079BQ37800929-F276AF8E-61FB-4D40-9E4D-DAC9C3109D5EQ37834018-6869C4DA-2A97-4D62-8489-4784EE40A200Q37836365-AF40E7F4-C454-403C-B829-27419E49D2BAQ37844966-40E9CD7A-C962-4DC6-96DA-22C976F61D02Q37846849-5E8CD5DD-618B-4999-BEF5-AD27ED11674F
P50
name
Jorma Paavonen
@en
Jorma Paavonen
@nl
type
label
Jorma Paavonen
@en
Jorma Paavonen
@nl
prefLabel
Jorma Paavonen
@en
Jorma Paavonen
@nl